AstraZeneca PLC (AZN)vsWeave Communications Inc (WEAV)
AZN
AstraZeneca PLC
$185.95
+0.76%
HEALTHCARE · Cap: $282.69B
WEAV
Weave Communications Inc
$5.69
-1.39%
HEALTHCARE · Cap: $434.43M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 24201% more annual revenue ($60.44B vs $248.72M). AZN leads profitability with a 17.2% profit margin vs -10.1%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
WEAV
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.1%
Fair Value
$194.57
Current Price
$185.95
$8.62 discount
Intrinsic value data unavailable for WEAV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
17.4% revenue growth
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -30.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : WEAV
The strongest argument for WEAV centers on Revenue Growth. Revenue growth of 17.4% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : WEAV
The primary concerns for WEAV are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while WEAV is a growth play — different risk/reward profiles.
WEAV carries more volatility with a beta of 1.69 — expect wider price swings.
WEAV is growing revenue faster at 17.4% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 32/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Weave Communications Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Weave Communications, Inc. provides a customer communication and interaction software platform in the United States and Canada. The company is headquartered in Lehi, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?